Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Many congratulations to Dr Beth Psaila, Dr Supat Thongjuea and Prof Andi Roy who were awarded fellowships to develop their independent research.

Dr Beth Psaila has been awarded an Advanced Clinician Scientist Fellowship from Cancer Research UK to study abnormal megakaryocytes and bone marrow fibrosis. She was also appointed as a Senior Fellow of New College, Oxford. This grant will enable Beth to establish an independent research group focusing on megakaryocyte biology in normal bone marrow and in patients with myeloproliferative neoplasms. Megakaryocytes are unique cells in the human body, responsible for generating all our circulating blood platelets and also producing growth factors that maintain and regulate the blood stem cell niches. Beth will use a combination of multi-omic single cell approaches, patient-derived xenograft models and highly-multiplexed in situ imaging to identify and validate new targets for therapy.

Dr Supat Thongjuea has been awarded a Oxford-Celgene Fellowship, which includes Celgene mentorship, to apply single-cell biology and computational methods to translational medicine challenges. The project aims to generate and validate new clinically-relevant biomarkers, therapies and targets. To do this Dr Thongjuea will work closely with Celgene to apply computational, statistical and machine learning algorithms to the development of new computational models. These will integrate multiple single-cell DNA, RNA and ATAC genomics datasets from patients undergoing clinical trials. This approach will be applied, for example, to address the issue of intratumoural heterogeneity, a major cause of therapy resistance. The work will be done in collaboration with the Vyas, Nerlov and Mead research groups and capitalises on the excellent single cell facilities at the MRC WIMM and the expertise of the MRC WIMM Centre for Computational Biology, where Dr Thongjuea is based.

Prof Anindita Roy, Associate Professor in the Department of Paediatrics, has been awarded a Wellcome Clinical Research Career Development Fellowship to study the developmentally-regulated changes in haematopoiesis that lead to treatment-resistant childhood leukaemias. The project will specifically focus on infant Acute Lymphoblastic Leukaemia (iALL), a type of cancer with high relapse rates and poor survival. These types of cancer are characterised by a translocation in the MLL gene, which takes place in utero. Prof Roy will examine at the molecular level why human fetal cells are particularly susceptible to this type of leukaemic transformation and how it progresses, using both in vitro and in vivo models. The ultimate aim of the research is to develop new and effective treatments for this condition.

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

RDM researchers awarded Oxford-Bristol Myers Squibb Fellowships

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Six new Oxford-BMS Fellowships for 2021 were announced.

New atlas revealed of bone marrow haematopoiesis during development

A new study published this week in Nature, provides the most detailed analysis so far of the prenatal development of blood and immune cells in the bone marrow.

Changes in blood cell production over the human lifetime may hold clues to patterns of disease

A new paper published this week in Cell Reports reveals that changes in the gene expression of blood stem cells occur across the human lifetime; an important step in the understanding and treatment of blood disorders.